Literature DB >> 24307459

Optimization of immune strategy for a construct of Salmonella-delivered ApxIA, ApxIIA, ApxIIIA and OmpA antigens of Actinobacillus pleuropneumoniae for prevention of porcine pleuropneumonia using a murine model.

Jin Hur1, John Hwa Lee.   

Abstract

In this study, the Actinobacillus pleuropneumoniae antigens ApxIA, ApxIIA, ApxIIIA and OmpA were expressed in an attenuated strain of Salmonella (∆lon∆cpxR∆asd) for prevention of porcine pleuropneumonia. In order to evaluate the immunization strategy of the construct, a total 60 BALB/c mice were equally divided into four groups (n = 15). Group A mice were intranasally immunized only at 6-weeks-of-age, while group B mice were intransally primed and boosted at 6- and 9-weeks-of-age, respectively, and group C mice were intransally primed at 6-weeks-of-age and subsequently boosted twice at 9- and 12-weeks-of-age. Group D mice were used as a control, which were inoculated with sterile PBS. Groups A, B, and C showed significantly higher serum IgG and fecal IgA immune responses than those of the control group. After virulent challenge with a wild type A. pleuropneumoniae, the immunized groups A, B and C showed 33.3 %, 13.3 % and 26.7 % mortality as the control group showed 60 % mortality. These results showed that the protection against porcine pleuropneumonia using the construct can be optimized by a double intranasal vaccination.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24307459     DOI: 10.1007/s11259-013-9586-6

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  20 in total

Review 1.  Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection.

Authors:  Janine T Bossé; Håkan Janson; Brian J Sheehan; Amanda J Beddek; Andrew N Rycroft; J Simon Kroll; Paul R Langford
Journal:  Microbes Infect       Date:  2002-02       Impact factor: 2.700

Review 2.  Efficacy of vaccines against bacterial diseases in swine: what can we expect?

Authors:  Freddy Haesebrouck; Frank Pasmans; Koen Chiers; Dominiek Maes; Richard Ducatelle; Annemie Decostere
Journal:  Vet Microbiol       Date:  2004-06-03       Impact factor: 3.293

Review 3.  New insights in mucosal vaccine development.

Authors:  Vincent Pavot; Nicolas Rochereau; Christian Genin; Bernard Verrier; Stéphane Paul
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

Review 4.  Mucosal immunity and vaccines.

Authors:  Jan Holmgren; Cecil Czerkinsky
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

Review 5.  Interaction of antigens and antibodies at mucosal surfaces.

Authors:  M E Lamm
Journal:  Annu Rev Microbiol       Date:  1997       Impact factor: 15.500

6.  An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines.

Authors:  J Q Tumamao; R E Bowles; H van den Bosch; H L B M Klaasen; B W Fenwick; P J Blackall
Journal:  Aust Vet J       Date:  2004-12       Impact factor: 1.281

7.  Intranasal vaccination in mice with an attenuated Salmonella enterica Serovar 908htr A expressing Cp15 of Cryptosporidium: impact of malnutrition with preservation of cytokine secretion.

Authors:  James K Roche; Ana Lara Rojo; Lourrany B Costa; Ronald Smeltz; Patricio Manque; Ute Woehlbier; Luther Bartelt; James Galen; Gregory Buck; Richard L Guerrant
Journal:  Vaccine       Date:  2012-12-16       Impact factor: 3.641

Review 8.  Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies.

Authors:  Mahendrasingh Ramjeet; Vincent Deslandes; Julien Gouré; Mario Jacques
Journal:  Anim Health Res Rev       Date:  2008-03-17       Impact factor: 2.615

9.  Cloning and characterization of the Actinobacillus pleuropneumoniae-RTX-toxin III (ApxIII) gene.

Authors:  R Jansen; J Briaire; E M Kamp; A L Gielkens; M A Smits
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

10.  Construction, characterization, and immunogenicity of an attenuated Salmonella enterica serovar typhimurium pgtE vaccine expressing fimbriae with integrated viral epitopes from the spiC promoter.

Authors:  Huaiqing Chen; Dieter M Schifferli
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more
  3 in total

1.  Immunoprotective Efficacy of Six In vivo-Induced Antigens against Actinobacillus pleuropneumoniae as Potential Vaccine Candidates in Murine Model.

Authors:  Fei Zhang; Sanjie Cao; Zhuang Zhu; Yusheng Yang; Xintian Wen; Yung-Fu Chang; Xiaobo Huang; Rui Wu; Yiping Wen; Qigui Yan; Yong Huang; Xiaoping Ma; Qin Zhao
Journal:  Front Microbiol       Date:  2016-10-21       Impact factor: 5.640

2.  Immunological study of an attenuated Salmonella Typhimurium expressing ApxIA, ApxIIA, ApxIIIA and OmpA of Actinobacillus pleuropneumoniae in a mouse model.

Authors:  Jin Hur; Seong Kug Eo; Sang-Youel Park; Yoonyoung Choi; John Hwa Lee
Journal:  J Vet Med Sci       Date:  2015-07-27       Impact factor: 1.267

3.  Genome-wide screening of lipoproteins in Actinobacillus pleuropneumoniae identifies three antigens that confer protection against virulent challenge.

Authors:  Yurou Cao; Lulu Gao; Li Zhang; Lixiang Zhou; Jihong Yang; Lingfu Deng; Jin Zhao; Chao Qi; Jinlin Liu
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.